To make disease-modifying first-in-class immuno-oncology treatments available to patients suffering from devastating conditions such as cancer
Medibiofarma focused internal resources on areas where lies the experience of the management team:
The remaining activities needed for the full compound characterization and the nomination of a development candidate, such as in vivo pharmacology and toxicology and IND-enabling studies are carried out through partnerships with several companies (CROs), Research Centers and Universities.
Medibiofarma participated in the “Startup Spotlight” event sponsored by Eli Lilly in the 13th edition of the annual BIO-Europe Spring conference 2019 held in Vienna. Julio Castro, CSO of...
Medibiofarma announces the completion of a new financing round of 2 million euros, with the financial support of its founder team and the incorporation of new partners, among them, Sodena, a...
